NexImmune, Inc.
GAITHERSBURG, MD · Founded 2011 · CIK 0001538210 · Biotech · Defunct
AIM nanoparticle platform for directing T cell responses in immunotherapy
neximmune.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $35M
- 7 Form D · Feb 2019
- 91 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 15
- 2 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201120122013201420152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $1,000 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $287,500 | |
| Private capital raised | Form D · SEC | $250,000 | |
| Private capital raised | Form D · SEC | $3,000,000 | |
| Private capital raised | Form D · SEC | $1,962,000 | |
| Private capital raised | Form D · SEC | $21,730,000 | |
| Private capital raised | Form D · SEC | $7,767,293 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2184 | CENNA BIOSCIENCES INC | — | — |
| 2185 | OCULOGENEX | — | — |
| 2186 | BIOSUPERIOR TECHNOLOGY INC | — | — |
| 2187 | NexImmune, Inc. | — | $35M |
| 2188 | Platform Therapeutics, Inc. | — | $1.8M |
| 2189 | Ceapro Inc. | — | $7.7M |
| 2190 | GREENSTONE BIOSCIENCES, INC. | — | $10M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- James BarrettDirector
- Timothy BertramDirector
- Alain CappelutiDirector · Executive Officer
- Slain CappelutiDirector · Executive Officer
- Scott CarmerDirector · Executive Officer
- Kenneth CarterDirector · Executive Officer
- Paul D'AngioDirector
- Janis NaeveDirector
- Alan RoemerDirector
- Jonathan SchneckDirector
- Robert SpiegelDirector
- Bing YaoDirector
- Tony YaoDirector
Patents
- Nanoparticle Compositions And Methods For Immunotherapyapplication
- Cell Compositions Comprising Antigen-specific T Cells For Adoptive Therapyapplication
- Nanoparticle Compositions And Methods For Immunotherapygranted
- Nanoparticle Compositions And Methods For Immunotherapygranted
- Injectable Artificial Antigen Presenting Cells For Immune Therapyapplication
- Combination Therapy With T Cell Engagerapplication
- Combination Therapy With T Cell Engagerapplication
- T Cell Compositions With Improved Phenotypic Propertiesapplication
- Cell Compositions Comprising Antigen-specific T Cells For Adoptive Therapyapplication
- Nanoparticle Compositions And Methods For Immunotherapyapplication
- Methods For Identifying Functional Neoantigens And Their Use In Cancer Immunotherapyapplication
- Injectable Artificial Antigen Presenting Cells For Immune Therapyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.